Press Release - May 8, 2026
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.1 pts more than Nifty Microcap 250 and 5.1 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Artemis Medicare Services reported strong Q4 FY26 consolidated results with revenue from operations of Rs 27,923 Lacs, up 16.4% YoY. EBITDA grew 23.1% to Rs 5,938 Lacs while PAT jumped 32.1% to Rs 3,028 Lacs. For the full year FY26, consolidated revenue was Rs 1,08,124 Lacs (up 15.4%), EBITDA Rs 21,801 Lacs (up 18.0%), and PAT Rs 10,372 Lacs (up 26.2%). The flagship Gurugram hospital showed ARPOB improvement to Rs 84,571 from Rs 78,835, with overseas patient revenue growing 13.5% to Rs 8,226 Lacs (30.8% contribution). Bed capacity utilisation was 64.6% for Q4. The company is expanding into Raipur to enter new high-growth markets.
Strong quarter with PAT growth exceeding 32% and EBITDA margin expansion signals solid operational leverage. The company's focus on high-acuity care and medical value travel is driving above-industry growth, which is positive for shareholders.